m6A甲基化:研究和治疗的新前沿
Mudasir Maqbool1, Yumna Khan2, Mohammed M Arab3
1Department of Pharmacology, Government Medical College, Baramulla, Jammu and Kashmir 193103, India.
EXCLI journal
|June 18, 2025
概括
在中,N6-甲基氨酸 (m6A) RNA的修改是至关重要的. m6A机制的失调会影响基因表达和神经元功能,为耐药性提供新的治疗标.
科学领域:
- 神经科学是一个神经科学.
- 分子生物学分子生物学
- 的研究研究.
背景情况:
- 是一种复杂的神经系统疾病,许多患者的治疗方法不足.
- N6-甲基氨酸 (m6A) RNA修饰正在成为与病理学相关的神经元过程的关键调节者.
研究的目的:
- 批判性地审查m6A修饰在的意义.
- 探索m6A在中"写字","擦"和"阅读"的作用.
- 讨论m6A调制作为治疗策略和生物标记物的潜力.
主要方法:
- 文献综述,重点关注m6ARNA修饰和的分子研究进展.
- 分析m6A机械在基因表达,神经元刺激性和突触可塑性中的作用.
- 讨论m6A变化作为预后生物标志物和治疗点.
主要成果:
- 对m6A机制的失调会加剧氧化应激,线粒体功能障碍和中神经元损伤.
- m6A的变化对的诊断和疾病进展具有预后意义.
- m6A调制为先进的治疗策略提供了潜力.
结论:
- m6A的修改在病原和进展中起着关键作用.
- 针对m6A机制为治疗耐药提供了有前途的途径.
- 基于m6A调节的个性化治疗策略可以改善患者的预后.
相关概念视频
Epilepsy and Seizures: Overview
297
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
297
Antiepileptic Drugs: GABAergic Pathway Potentiators
685
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
685
Antiepileptic Drugs: Glutamate Antagonists
528
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
528
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
463
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
463
Antiepileptic Drugs: Potassium Channel Activators
291
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
291


